JIB-097 is a dual LSD1 and histone deacetylase 6 (HDAC6) inhibitor, which was tested against various cancer types, e.g., in multiple myeloma MM1.S cells-derived mice xenograft, and its combination with bortezomib or pomalidomide enhanced tumor volume reduction [181]. Here, HDAC6 is linked to neoplasm.